ArticleTexas Heart Institute journal2007
A history of streptokinase use in acute myocardial infarction.
Article in Texas Heart Institute journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Intrapleural Fibrinolytic Therapy in the Management of Pediatric Pleural Empyema: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Maggot Kinase and Natural Thrombolytic Proteins.ACS omega · 2024Review
- Fibrin and Fibrinolytic Enzyme Cascade in Thrombosis: Unravelling the Role.Life (Basel, Switzerland) · 2023Review
- Review
- A Brief Review of Thrombolytics for Venous Interventions.Seminars in interventional radiology · 2022Review
- Myeloperoxidase and troponin T are linked with myocardial infarction among young Indians.Bioinformation · 2022Article
- Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.Molecular biology reports · 2020Review
- Stability of Therapeutic Enzymes: Challenges and Recent Advances.Advances in experimental medicine and biology · 2019Review
- Fibrinolytic Enzymes for Thrombolytic Therapy.Advances in experimental medicine and biology · 2019Review
- Modulation of Host Immunity by Helminths: The Expanding Repertoire of Parasite Effector Molecules.Immunity · 2018Review
- Autopsy and Imaging Studies of Mucus in Asthma. Lessons Learned about Disease Mechanisms and the Role of Mucus in Airflow Obstruction.Annals of the American Thoracic Society · 2018Review
- Elongated Plant Virus-Based Nanoparticles for Enhanced Delivery of Thrombolytic Therapies.Molecular pharmaceutics · 2017Article
- The evolution of recombinant thrombolytics: Current status and future directions.Bioengineered · 2017Article
- Zinc chelation promotes streptokinase-induced thrombolysisInternational journal of physiology, pathophysiology and pharmacology · 2017Article
- Complete genome sequence of Streptococcus agalactiae strain GBS85147 serotype of type Ia isolated from human oropharynx.Standards in genomic sciences · 2016Article
- PEGylation of Truncated Streptokinase Leads to Formulation of a Useful Drug with Ameliorated Attributes.PloS one · 2016Article
- 25 by 25: Achieving Global Reduction in Cardiovascular Mortality.Current cardiology reports · 2016Review
- Pathogen activators of plasminogen.Journal of thrombosis and haemostasis : JTH · 2015Review
- Management and outcomes of acute ST-segment-elevation myocardial infarction at a tertiary-care hospital in Sri Lanka: an observational study.BMC cardiovascular disorders · 2015Observational
- Production of recombinant streptokinase from Streptococcus pyogenes isolate and its potential for thrombolytic therapy.Saudi medical journal · 2014Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A serendipitous discovery by William Smith Tillett in 1933, followed by many years of work with his student Sol Sherry, laid a sound foundation for the use of streptokinase as a thrombolytic agent in the treatment of acute myocardial infarction. The drug found initial clinical application in combating fibrinous pleural exudates, hemothorax, and tuberculous meningitis. In 1958, Sherry and others started using streptokinase in patients with acute myocardial infarction and changed the focus of treatment from palliation to "cure." Initial trials that used streptokinase infusion produced conflicting results. An innovative approach of intracoronary streptokinase infusion was initiated by Rentrop and colleagues in 1979. Subsequently, larger trials of intracoronary infusion achieved reperfusion rates ranging from 70% to 90%. The need for a meticulously planned and systematically executed randomized multicenter trial was fulfilled by the Gruppo Italiano per la Sperimentazione della Streptochinasi nell'Infarto Miocardico (GISSI) trial in 1986, which not only validated streptokinase as an effective therapeutic method but also established a fixed protocol for its use in acute myocardial infarction. Currently, despite the wide use of tissue plasminogen activator in developed nations, streptokinase remains essential to the management of acute myocardial infarction in developing nations.
Indexed as
Identifiers
17948083PMC1995058What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.